Sepracor Submits Xopenex HFA NDA; Inhaler Could Triple Target Population
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Approval of Sepracor’s metered dose version of levalbuterol, Xopenex HFA, could triple the target population for the bronchodilator, the firm indicated.